References
- Egeler RM, D'Angio GJ. Langerhans cell histiocytosis. J Pediatr 1995;127:1–11.
- Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child 2009;94:376–80.
- Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 1997;28:9–14.
- Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ. Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome. Cancer 1999;85:2278–90.
- Gotz G, Fichter J. Langerhans’– cell histiocytosis in 58 adults. Eur J Med Res 2004;9:510–4.
- Satter EK, High WA. Langerhans cell histiocytosis: A review of the current recommendations of the Histiocyte Society. Pediatr Dermatol 2008;25:291–5.
- McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 2007;48:44–9.
- Misery L, Larbre B, Lyonnet S, Faure M, Thivolet J. Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin Exp Dermatol 1993;18:487.
- Palumbo A, Rajkumar SV. Multiple myeloma: Chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010;84:379–90.
- Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma 2008;49:1238–45.